抗体(antibody)毒素(drug)连接物(linker)构建ADC-抗体药物偶连物 ADCs的组成包括肿瘤抗原特异性mAb,稳定的可裂解或不可裂解的linker,以及有效的细胞毒性载荷。 rug)、连接物(linker)构建ADC-抗体药物偶连物 ADCs的组成包括肿瘤抗原特异性mAb,稳定的可裂解或不可裂解的linker,以及有效的细胞毒性载荷。 ADC由以下三部分组成: 抗体(antibody):其作用是特异性识别靶细胞 毒素(drug):起到损伤细胞的作用 连接物(linker):连接抗体与毒素 ![]()
相关资料: DBCO-PEG4-vc-PAB-MMAE DBCO-PEG4-MMAF DBCO-PEG4-Ahx-DM1 DBCO-PEG4-vc-PAB-Duocarmycin SA DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin SA DBCO-PEG4-VA-PBD DBCO-PEG4-vc-PAB-MMAF DBCO-PEG4-vc-PAB-MMAD DBCO-PEG4-vc-PAB-Duocarmycin TM DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin TM DBCO-PEG4-vc-PAB-Duocarmycin DM DBCO-PEG4-vc-PAB-(PEG2)-Duocarmycin DM DBCO-PEG4-VC-PAB-DMAE-PNU159682 DBCO-PEG4-DMAE-PNU159682 DBCO-PEG4-GGFG-DX8951 DBCO-PEG4-vc-PAB-Ahx-DM1 DBCO-PEG8-VA-PAB-SG3199 Gly3-vc-PAB-MMAE Gly3-MMAF Gly5-Ahx-DM1 PNU159682-EDA-Gly3 ADC pre-screening kit A Protein A-DM1 Protein A-MMAE Protein A-MMAF Protein A-Duocarmycin Protein A-Calicheamicin Protein A-PBD ADC pre-screening kit G Protein G-DM1 Protein G-MMAE Protein G-MMAF Protein G-Duocarmycin Protein G-Amanitin Protein G-Amanitin Rabbit Anti-vc-PAB-MMAE pAb Mouse Anti-vc-PAB-MMAE mAb (B11F11) Rabbit Anti-MMAF pAb Mouse Anti-MMAF mAb (F3B11) Mouse Anti-MMAE / F mAb (B12A2) Mouse Anti-MMAE /F mAb (C12A1) Rabbit Anti-DM1/4 pAb Mouse Anti-DM1/4 mAb (F1D5) Mouse Anti-DM1/4 mAb (G2F3) Rabbit Anti-Calicheamicin pAb Mouse Anti-Calicheamicin mAb (B1G9) Mouse Anti-Calicheamicin mAb (C1F12) Rabbit Anti-Duocarmycin pAb Mouse Anti-Duocarmycin mAb (E11A1) Mouse Anti-Duocarmycin mAb (H7A9) Mouse Anti-Duocarmycin mAb (E6B3) Rabbit Anti-PNU-159682 pAb Mouse Anti-PNU-159682 mAb (F7F2) Mouse Anti-PNU-159682 mAb (C1E3) Mouse Anti-PNU-159682 mAb (D12H11) Rabbit Anti-Amanitin pAb Mouse Anti-Amanitin mAb (H3E1) Mouse Anti-Amanitin mAb (H12D6) Mouse Anti-Amanitin mAb (C2C4) Rabbit Anti-SN38 pAb Mouse Anti-SN38 mAb (10F11A9D6) Mouse Anti-SN38 mAb (8E10F12F3) Mouse Anti-SN38 mAb (8E10A4A1) Rabbit Anti-PBD SG3199 pAb Mouse Anti-PBD SG3199 (7H6H9A6) mAb Mouse Anti-PBD SG3199 (8G2H12A9) mAb Mouse Anti-PBD SG3199 (8B3D12G1) mAb 资料仅供科研参考,其他合成技术疑问欢迎探讨(2021.4.lrx ) |
|
来自: Stargraydye > 《待分类》